Insys Must Divest Subsys, Buprenorphine Candidate Products As Part Of Corporate Integrity Agreement
Executive Summary
Settlement with US government also includes $225m payment to resolve criminal and civil cases related to illegal marketing of the sublingual fentanyl spray Subsys.
You may also be interested in...
Purdue Pharma: From Blockbuster Success To Bankrupt Villain
Purdue's rise and fall through opioids will likely end in bankruptcy, raising new questions around ongoing lawsuits and shining a light on the toll the opioid liability will leave on the industry.
Keeping Track: US Approvals For Xpovio And Xembify Highlight Short Holiday Week
The latest drug development news and highlights from our US FDA Performance Tracker.
J&J Gambles Oklahoma Opioid Trial Is Better Than Settlement; State Seeks $870m Per Year
In opening statements, Oklahoma suggests award could be 'just shy of $13bn' if it takes 20 years to fix the problem.